01
Dec
2008
Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - RNAi, X - Target ID
Biomics Biotechnologies (China) development-stage company focused on target identification and RNAi therapeutics, closed a $5M Series B financing. Participants include Jiangsu Dinghong Venture Capital and Jiangsu Benefit Rise Group.